429 related articles for article (PubMed ID: 33664857)
1. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
2. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
[TBL] [Abstract][Full Text] [Related]
3. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
4. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
6. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
7. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer.
Devalapally H; Duan Z; Seiden MV; Amiji MM
Int J Cancer; 2007 Oct; 121(8):1830-8. PubMed ID: 17557285
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
Duan Z; Brakora KA; Seiden MV
Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.
Zhang C; Zhao Y; Zhang E; Jiang M; Zhi D; Chen H; Cui S; Zhen Y; Cui J; Zhang S
Drug Deliv; 2020 Dec; 27(1):1397-1411. PubMed ID: 33096948
[TBL] [Abstract][Full Text] [Related]
11. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
12. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
[TBL] [Abstract][Full Text] [Related]
13. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo.
Yao S; Li L; Su XT; Wang K; Lu ZJ; Yuan CZ; Feng JB; Yan S; Kong BH; Song K
J Exp Clin Cancer Res; 2018 Feb; 37(1):29. PubMed ID: 29478415
[TBL] [Abstract][Full Text] [Related]
15. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
16. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.
Zhao MD; Li JQ; Chen FY; Dong W; Wen LJ; Fei WD; Zhang X; Yang PL; Zhang XM; Zheng CH
Int J Nanomedicine; 2019; 14():9453-9467. PubMed ID: 31819443
[TBL] [Abstract][Full Text] [Related]
17. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
[TBL] [Abstract][Full Text] [Related]
18. GSH-responsive poly-resveratrol based nanoparticles for effective drug delivery and reversing multidrug resistance.
Liping Y; Jian H; Zhenchao T; Yan Z; Jing Y; Yangyang Z; Jing G; Liting Q
Drug Deliv; 2022 Dec; 29(1):229-237. PubMed ID: 35001781
[TBL] [Abstract][Full Text] [Related]
19. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
20. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
